Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
What happens to ΔF508 in vivo?
Mitchell Drumm
Mitchell Drumm
Published May 15, 1999
Citation Information: J Clin Invest. 1999;103(10):1369-1370. https://doi.org/10.1172/JCI7119.
View: Text | PDF
Commentary Article has an altmetric score of 3

What happens to ΔF508 in vivo?

  • Text
  • PDF
Abstract

Authors

Mitchell Drumm

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Under heterologous cell culture conditions (top), only wild-type (WT) CF...
Under heterologous cell culture conditions (top), only wild-type (WT) CFTR shows cAMP-stimulated channel activity. Only when manipulated to induce trafficking to the membrane (top right) does ΔF508 show any detectable channel activity. Tissue-specific differences in CFTR localization described by Kälin et al. are seen between epithelia of the sweat gland and epithelia of the airway and intestines (bottom). Whereas ΔF508 in the membrane of transfected cells responds to cAMP (top right), ΔF508 in endogenously expressing airway and intestinal cells (bottom right) does not.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 clinical guideline sources
8 readers on Mendeley
See more details